Swedish Orphan Biovitrum AB (publ)

Total Valuation

Swedish Orphan Biovitrum AB (publ) carries a market capitalization of 17.03B, placing it among publicly traded companies globally. Its enterprise value stands at 107.23B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Swedish Orphan Biovitrum AB (publ) currently has 344.61M shares outstanding.

Valuation Ratios

Swedish Orphan Biovitrum AB (publ) trades at a trailing price-to-earnings ratio of 21.84. The price-to-sales ratio is 3.54, and the price-to-book ratio stands at 4.04.

Enterprise Valuation

On an enterprise value basis, Swedish Orphan Biovitrum AB (publ) trades at an EV/EBITDA multiple of 17.28 and an EV/FCF ratio of 11.39. The EV/Sales ratio of 3.98 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 17.28 provides insight into valuation relative to core operating earnings.

Financial Position

Swedish Orphan Biovitrum AB (publ) maintains a current ratio of 1.00, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities.

Financial Efficiency

Swedish Orphan Biovitrum AB (publ) posts a return on equity of 20.39 and a return on invested capital of 10.20.

Taxes

Over the trailing twelve months, Swedish Orphan Biovitrum AB (publ) has paid 676.00M in income taxes, reflecting an effective tax rate of 13.42.

Stock Price Statistics

Swedish Orphan Biovitrum AB (publ)'s stock has gained approximately 64.57872% over the past 52 weeks. The 50-day moving average sits at 48.00, while the 200-day moving average is 39.92.

Income Statement

Over the trailing twelve months, Swedish Orphan Biovitrum AB (publ) generated 26.97B in revenue and converted that into 4.37B in net income, yielding earnings per share of 12.57. EBITDA reached 6.21B, while operating income came in at 6.21B.

Balance Sheet

Swedish Orphan Biovitrum AB (publ) holds 1.06B in cash and equivalents against 12.81B in total debt, resulting in a net debt position of 11.39B. Total book value stands at 23.63B, with working capital of 27.00M providing operational flexibility.

Cash Flow

Swedish Orphan Biovitrum AB (publ) produced 6.74B in operating cash flow over the past twelve months. After subtracting -2.67B in capital expenditures, free cash flow totaled 4.07B - equivalent to 11.85 per share.

Margins

Swedish Orphan Biovitrum AB (publ) operates with a gross margin of 77.95, reflecting its pricing power and cost economics. The operating margin of 23.01 and net profit margin of 16.21 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Swedish Orphan Biovitrum AB (publ)'s most recent stock split took place on August 28, 2023 with a 500:523 split ratio.

Scores

Swedish Orphan Biovitrum AB (publ) posts an Altman Z-Score of 7.19, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.